Methotrexate management for placenta accreta: a prospective study
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objective To observe efficacy following methotrexate (MTX) management in women with placenta accreta. Methods Twenty-four stable patients with placenta accreta were treated with MTX. Beta-hCG values, vascular indices of the residual placenta, and other clinical characteristics were collected prospectively and were compared between the success and failure groups. Results After MTX management, the residual placentas were expulsed spontaneously in 33.3% of the patients. This was done through dilatation and curettage (D & C) in 45.8% of the patients. The residuals in the uterine wall were completely absorbed within 5.7 months. In the patients who were successfully treated with MTX, their beta-hCG values and vascular indices of the placentas decreased faster than those of failure patients (P Conclusions MTX management, when the beta-hCG value and vascular indices of placenta decreased significantly, is a conservative option for a stable patient with placenta accreta in China. 3D power Doppler ultrasound should be utilized for the follow-up of this condition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One woman did suffer liver damage and the risks of this therapy must be balanced against the unproven benefit.”
From Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green‐top Guideline No. 27a (2019) · cites this paper as [197]
In the citing paper
“There was no control group of women who did not receive MTX and so it is unknown whether or not the MTX was clinically helpful.”
From Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green‐top Guideline No. 27a (2019) · cites this paper as [197]
In the citing paper
“An observational case series, including 24 women with placenta accreta left in situ after delivery and treated with MTX, reported placental delivery in 33.3% of the cases (spontaneously in 55%, and in 45% following dilatation and surgical evacuation).197”
From Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green‐top Guideline No. 27a (2019) · cites this paper as [197]
Citations
Cites
Three‐dimensional power Doppler sonography: imaging and quantifying blood flow and vascularization
Pairleitner, H., Steiner, H., Hasenoehrl, G., & Staudach, A. (1999) · Ultrasound in Obstetrics & Gynecology · doi:10.1046/j.1469-0705.1999.14020139.x · Cited by 388
Placenta Accreta—Summary of 10 Years: A Survey of 310 Cases
Gielchinsky, Y., Rojansky, N., Fasouliotis, S. J., & Ezra, Y. (2002) · Placenta · doi:10.1053/plac.2001.0764 · Cited by 376 · cited 1×
“The diagnosis of placenta accreta was based on clinical or histological findings [6], including the presence of the following: (a) difficult manual, piecemeal removal of the placenta was performed if no evidence of placental separation was noticed at least 20 min after parturition, and despite active management of the…”
MethodConservative Management of Abnormally Invasive Placentation
Timmermans, S., van Hof, A. C., & Duvekot, J. J. (2007) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000271133.27011.05 · Cited by 270 · cited 2×
“7 % (2/3), respectively, in women suffered from placenta accreta without additional treatments [11], poorer than the present outcome with 33.”
ResultShih, J. C., Jaraquemada, J. M. P., Su, Y. N., Shyu, M. K., Lin, C. H., Lin, S. Y., & Lee, C. N. (2009) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.6284 · Cited by 249
FOX, H. (1972) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-197207000-00001 · Cited by 218 · cited 1×
“Conventional management of this condition has long been extirpative given that mortality rates approached 25 % with conservative measures, but these rates were lowered to only 6 % with prompt hysterectomy [1].”
BackgroundSecondary postpartum haemorrhage: incidence, morbidity and current management
Hoveyda, F., & MacKenzie, I. Z. (2001) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2001.00230.x · Cited by 180 · cited 1×
“This is often a result of attempted manual placental separation from its poorly formed decidual bed, which opens up large-caliber spiral vessels and sinuses [9].”
BackgroundMedical Treatment of Placenta Accreta with Methotrexate
Arulkumaran, S., Ng, C. S. A., Ingemarsson, I., & Ratnam, S. S. (1986) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.3109/00016348609155187 · Cited by 153 · cited 1×
“Therefore, MTX is assumed to affect the placental tissue by reducing its vascularity, leading to placental necrosis and thus rapid placental involution [5, 12, 13].”
BackgroundCommittee opinion #270: bone density screening for osteoporosis
Committee on Gynecologic Practice (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)01943-9 · Cited by 132
Diagnosis and management of placenta accreta
Palacios-Jaraquemada, J. M. (2008) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2008.08.003 · Cited by 123
de Paula, C. F. S., Ruano, R., Campos, J. A. D. B., & Zugaib, M. (2009) · Placenta · doi:10.1016/j.placenta.2008.11.010 · Cited by 111 · cited 1×
“This way, the quantitative blood flow [14, 15] and placental involution situation [16, 17] were derived.”
Background
Cited by
Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green‐top Guideline No. 27a
Jauniaux, E., Alfirevic, Z., Bhide, A., Belfort, M., Burton, G., Collins, S., Dornan, S., Jurkovic, D., Kayem, G., Kingdom, J., et al. (2019) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15306 · Cited by 506
“3% of the cases (spontaneously in 55%, and in 45% following dilatation and surgical evacuation).(197) There was no control group of women who did not receive MTX and so it is unknown whether or not the MTX was clinically helpful.”
BackgroundFIGO consensus guidelines on placenta accreta spectrum disorders: Conservative management,
Sentilhes, L., Kayem, G., Chandraharan, E., Palacios‐Jaraquemada, J., Jauniaux, E., & Panel, F. T. F. P. A. D. A. M. E. C. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12410 · Cited by 322
Cui, R., Li, M., Lu, J., Bai, H., & Zhang, Z. (2018) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-018-1935-6 · Cited by 39
Karaman, E., Kolusarı, A., Çetin, O., Çim, N., Alkış, İ., Yıldızhan, R., Şahin, H. G., & Gül, A. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2016.1192119 · Cited by 35
Fitzgerald, G. D., Newton, J. M., Atasi, L. K., Duzyj, C. M., Luna, J. M. B., Burnett, B., Carver, A. R., Cheng, C., Conyers, S., Davitt, C. C., et al. (2023) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2023.101229 · Cited by 35
Wei, Y., Cao, Y., Yu, Y., & Wang, Z. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4447-0 · Cited by 34
Berhan, Y., & Urgie, T. (2020) · Ethiopian Journal of Health Sciences · doi:10.4314/ejhs.v30i2.16 · Cited by 36
“However, there are some success stories (spontaneous placental expulsion and faster complete involution) reported from the case series studies with methotrexate administration (67-69).”
BackgroundPlacenta Accreta Spectrum: A Comprehensive Review of Guidelines
Giouleka, S., Tsakiridis, I. G., Chanioti, E.-R., Ladas, K., Liberis, A., Mamopoulos, A. M., Kalogiannidis, I. A., Athanasiadis, A. P., & Dagklis, T. (2024) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001274 · Cited by 24
“71 However, nowadays, this intervention is unanimously not recommended due to the associated adverse effects 65 and the insufficient evidence regarding its efficacy, as a study of 22 women who received adjuvant methotrexate concluded that the benefits of this approach remain uncertain.”
BackgroundManagement of Abnormal Placenta Implantation with Methotrexate: A Review of Published Data
Farasatinasab, M., Moghaddas, A., Dashti-Khadivaki, S., Raoofi, Z., & Nasiripour, S. (2016) · Gynecologic and Obstetric Investigation · doi:10.1159/000447556 · Cited by 26
Ou, J., Peng, P., Teng, L., Li, C., & Liu, X. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2019.09.014 · Cited by 22
Placenta Accreta Spectrum: Conservative Management and Its Impact on Future Fertility
Abbas, R. A., & Nassar, A. H. (2020) · Maternal-Fetal Medicine · doi:10.1097/fm9.0000000000000077 · Cited by 25
“17,36 However, its ef fi cacy in PAS may be limited.”
BackgroundWang, Z., Li, X., Pan, J., Zhang, X., Shi, H.-F., Yang, N., & Jin, Z. (2016) · Chinese Medical Sciences Journal · doi:10.1016/s1001-9294(17)30005-6 · Cited by 19
Conservative Surgical Management of Placenta Accreta Spectrum: A Pragmatic Approach
Sichitiu, J., El-Tani, Z., Mathevet, P., & Desseauve, D. (2019) · Journal of Investigative Surgery · doi:10.1080/08941939.2019.1623956 · Cited by 18
The risk of placenta accreta following primary cesarean delivery
Zeevi, G., Tirosh, D., Baron, J., Yitshak‐Sade, M., Segal, A., & Hershkovitz, R. (2018) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-4698-4 · Cited by 20
Morbidly Adherent Placenta: Interprofessional Management Strategies for the Intrapartum Period
Baird, S. M., Troiano, N. H., & Kennedy, M. (2016) · The Journal of Perinatal & Neonatal Nursing · doi:10.1097/jpn.0000000000000209 · Cited by 17
High‐intensity focused ultrasound in management of placenta accreta spectrum: A systematic review
Elazeem, H. A. S. A., Saad, M. M., Ahmed, I., Sayed, E. G., AlMahdy, A. M., Atef, F., Elassall, G. M., Salah, M. A., Ali, A. K., Ragab, E. Y., et al. (2020) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13391 · Cited by 14
“Sixty-one articles were retrieved from our CON-PAS registry on conservative management using UAE (23 studies) (26-48), prophylactic balloon placement (15 studies) (49-63), compression sutures (10 studies) (64-73), leaving placenta in situ (7 studies) (74-80), and uterine wall excision and reconstruction (6 studies) (8…”
MethodPlacenta Praevia and Placenta Accreta Spectrum: Diagnosis and Management
Jauniaux, E. R. M., Bhide, A., Hussein, A. M., Lees, C. C., D'Antonio, F., Robson, S. C., Agten, A. K., & Jurkovic, D. (2026) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.70239 · Cited by 14
“An observational case series, including 24 women with PAS where the placenta was left in situ after birth and treated with MTX, reported placental delivery in 33.3% of the cases (spontaneously in 55% and in 45% following surgical evacuation) [252].”
InfluentialYuan, Y., He, X., Liu, P., Pu, D., Shi, Q., Chen, J., Teichmann, A. T., & Zhan, P. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06840-6 · Cited by 8
“To hasten placental resolution, methotrexate is used, although there have been controversies concerning its effectiveness [5].”
BackgroundThe use of methotrexate in conservative treatment of placenta accreta spectrum disorders
Gregoir, C., Becker, B. D., Hauspy, J., Vanderheyden, T., & Loquet, P. (2021) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2021.1951211 · Cited by 8
“In 2014 a prospective study on the management for placenta accreta with MTX was published [13].”
BackgroundConservative Surgical Treatment of a Case of Placenta Accreta
Bıyık, İ., Keskin, F., & Keskin, E. U. (2018) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0038-1668528 · Cited by 6
Conservative Management of Abnormally Invasive Placenta Previa after Midtrimester Foetal Demise
MacGibbon, A. L., & Ius, Y. (2018) · Case Reports in Obstetrics and Gynecology · doi:10.1155/2018/7478437 · Cited by 6
“There is currently no clear evidence as to the benefit of methotrexate in conservative management of placenta accreta after delivery [12].”
Clinical insights into placenta accreta spectrum: a comprehensive review
Lee, S., & Kim, S. C. (2025) · Obstetrics & Gynecology Science · doi:10.5468/ogs.25231 · Cited by 5
“A recent observational case series involving 24 women with retained placenta in situ who received MTX reported placental expulsion in approximately 33.3% of cases, with 55% spontaneous and 45% achieved by dilation and curettage [74].”
InfluentialArenas, G. A., Thompson, J. J., & Pineles, B. L. (2024) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-024-00395-w · Cited by 5
“…e d a t a t o s uppo r t i m p r ov e d m a t e r n a l ou t c o m e s a nd acce l e r a t e d p l ace n t a l r e s o l u ti on r a t e [ 40 • , 41–44 ] U t e r i n e a r t e r y e m bo li za ti on i s no t r ou ti n e l y r ec o mm e nd e d f o r s u r g i ca l r i s k p r e v e n ti on ( E v i…”
The Management of Placenta Accreta Spectrum Disorder
Donovan, B. M., & Zuckerwise, L. C. (2025) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000942 · Cited by 4
Conservative vs. Radical Management of Placenta Accreta Spectrum (PAS)
Palacios-Jaraquemada, J. M. (2020) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-019-00274-9 · Cited by 4
The use of methotrexate in the management of placenta accreta spectrum: a narrative review
Nohra, L., Nafeh, G., Assi, M., & Chbib, D. E. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003524 · Cited by 3
“Moreover, the use of methotrexate for placenta accreta management during previous case reports showed a decrease in beta-hCG, vascular indices decreased significantly and a decrease in the size of the partial placenta retained [ 3 , 4 ] .”
InfluentialFramarino‐dei‐Malatesta, M. (2016) · Journal of Clinical Case Reports · doi:10.4172/2165-7920.1000706 · Cited by 4
“Volume 6 • Issue 2 • 1000706 J Clin Case Rep ISSN: 2165-7920 JCCR, an open access journal accreta so that the role of MTX to improve the feasibility and success rate of conservative management and placental resorption needs further studies [30].”
BackgroundMethodInfluentialMethotrexate Induces Apoptosis of Postpartum Placental Cytotrophoblasts
Yan, H., Li, Z., Yan, Z., Li, X., Li, X., Yu, L., Su, C., & Chen, D. (2017) · Cells Tissues Organs · doi:10.1159/000452947 · Cited by 2
“Quantitative Detection of HCG-β by ELISA The differentiation of cytotrophoblasts into syncytiotrophoblasts is known to parallel the increased expression of HCG-β [Hohn and Denker, 2002].”
BackgroundInfluentialUysal, G., OKÇU, N. T., ESKİMEZ, E., & Yılmaz, E. S. (2019) · The European Research Journal · doi:10.18621/eurj.382390 · Cited by 1
“Conservative managementsinclude; leaving the placenta in situ, hysteroscopic resection of retained adherent placenta, partial en bloc resection with embolization, the Triple P procedure which involves perioperative placental localization, pelvic devascularization, myometrial excision with non-seperated placenta and re…”
BackgroundMethodKhan, Y. L., Rahim, A., Gardezi, J. R., Iqbal, M., Hassan, Z., Altaf, S., & Bhatti, S. (2018) · Clinical Case Reports · doi:10.1002/ccr3.1717 · Cited by 1
Sengupta, R., Gimovsky, A. C., Wei, S. Q., Bamigboye, A. A., Berghella, V., Adegboye, A. R. A., & Fraser, W. D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012159 · Cited by 1
RetractedKellie, F. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012159.pub2
Conservative Management of Placenta Accreta of Seven Cases
Fakhir, B., Zaki, M., Harou, K., Bassir, A., Boukhan, L., Aitbenkeddour, Y., Asmouki, H., & Soummani, A. (2018) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2018.87070 · Cited by 1
“Its use as an auxiliary treatment to reduce placental mass is not well proven to date [8] [10].”
BackgroundSuccessful Postpartum Outcome of Placenta In Situ in a Case of Placenta Percreta: A Case Study
Suren, P., Garg, S., Thakral, V., Sharma, G., Sharma, U., & Bansal, N. O. (2021) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-021-01513-x
Maulina, F., Dilmy, M. A. F., Saroyo, Y. B., & Purwosunu, Y. (2021) · Majalah Obstetri & Ginekologi · doi:10.20473/mog.v29i32021.129-135 · Cited by 1
Evidence-Based Management of Placenta Accreta Spectrum
Shazly, S. A., Radwan, A. A., AlMahdy, A. M., Ateya, M. I., Abouzeid, M. H., Sayed, E. G., & Elassall, G. M. (2022) · Springer eBooks · doi:10.1007/978-3-031-10347-6_11
Daiho, S., Iwagoi, Y., Sagara, A., Shimokawa, R., Yoshimura, S., Kobayashi, M., Ochiai, M., Yamamoto, Y., Yamaguchi, M., Mogami, H., et al. (2026) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.70447
“Methotrexate (MTX) has been used as an adjunct to conservative management with the aim of accelerating placental resorption by targeting trophoblastic tissue [5].”
Staged management of an extensive placenta percreta: a case report
Hopp, S., Raible, M., Cue, L., Einstein, M., & Bruck, L. R. (2026) · Journal of Medical Case Reports · doi:10.1186/s13256-026-06628-1
Metadata
- Authors
- Lin, K., Qin, J., Xu, K., Hu, W., & Lin, J.
- Affiliations
- Women's Hospital, School of Medicine, Zhejiang University (CN)
- Corresponding author
- Lin, Jun
- Venue
- Archives of Gynecology and Obstetrics
- Published
- 2014-12-11
- Volume
- 291
- Issue
- 6
- Pages
- 1259-1264
- ISSN
- 0003-9128 (ISSN-L)
- 0932-0067
- 1432-0711
- OpenAlex
- W2037046030
- Cited by
- 39
- References
- 22
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 9 · 2017: 3 · 2016: 6
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Archives of Gynecology and Obstetrics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Maternal and fetal healthcare
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Trophoblastic Disease Studies
- Keywords
- placenta accreta, methotrexate, conservative treatment, spontaneous expulsion, dilatation and curettage, beta-hCG, placental vascularization, power Doppler, postpartum hemorrhage prevention
- MeSH terms
- Adult, China, Dilatation and Curettage, Female, Follow-Up Studies, Humans, Methotrexate, Placenta, Placenta Accreta, Pregnancy, Prospective Studies, Ultrasonography, Uterus, Chorionic Gonadotropin, beta Subunit, Human, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.